FDG Positron Emission Tomography

OTHER3 trials

Sponsors

Wuerzburg University Hospital, Centre Georges Francois Leclerc, Mayo Clinic

Conditions

Adrenal NeoplasiaCNS MalignancyCarcinoma, Hepatocellular

Phase 3

Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia

TerminatedNCT02010957

Wuerzburg University HospitalAdrenal Neoplasia

Start: 2015-07-31End: 2022-07-31Updated: 2025-06-10

Unknown Phase

Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

TerminatedNCT02847468

Centre Georges Francois LeclercCarcinoma, Hepatocellular

Start: 2017-03-27End: 2021-12-23Updated: 2023-10-11

A Study of Metabolic Agents Following Brain Radiation

CompletedNCT06150547

Mayo ClinicCNS Malignancy

Start: 2023-12-27End: 2025-08-04Updated: 2025-08-12

Related Papers

Combined [<sup>18</sup>F]Fluorodeoxyglucose PET and [<sup>123</sup>I]Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias-the cross-sectional diagnostic test accuracy study FAMIAN.

2025-05-201 citations